Finance

Lists
Why is LILY34 up 3,19%?
Dive Deeper
LILY34:BVMF
Eli Lilly And Company BDR
198,64 R$
+3,19%
(+6,14) 1D
7 ოქტ, 16:32:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for LILY34...
Open
194,10 R$
High
200,82 R$
Low
193,98 R$
Mkt. cap
1,12 ტრლ.
Avg. vol.
36,37 ათ.
Volume
37,57 ათ.
52-wk high
223,07 R$
52-wk low
141,56 R$
Shares outstanding
941,36 მლნ.
No. of employees
50 ათ.
Open
194,10 R$
High
200,82 R$
Low
193,98 R$
Mkt. cap
1,12 ტრლ.
Avg. vol.
36,37 ათ.
Volume
37,57 ათ.
52-wk high
223,07 R$
52-wk low
141,56 R$
Shares outstanding
941,36 მლნ.
No. of employees
50 ათ.
News stories
From web sources and news partners
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEOდეივიდ ეი რიკსი
Employees50 ათ.
Founded1876
Headquartersინდიანაპოლისი, ინდიანა, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websitelilly.com
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
8,38 US$ / 6,58 US$
+27,27%beat
Revenue / Est. (USD)
22,97 მლრდ. / 20,69 მლრდ.
+11,06%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
17,60 მლრდ.
19,29 მლრდ.
19,80 მლრდ.
22,97 მლრდ.
Cost of goods sold
3,01 მლრდ.
3,37 მლრდ.
3,58 მლრდ.
3,27 მლრდ.
Cost of revenue
3,01 მლრდ.
3,37 მლრდ.
3,58 მლრდ.
3,27 მლრდ.
Research and development expenses
3,47 მლრდ.
3,80 მლრდ.
3,51 მლრდ.
3,82 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,63 მლრდ.
3,46 მლრდ.
2,93 მლრდ.
3,43 მლრდ.
Operating expense
6,09 მლრდ.
7,26 მლრდ.
6,44 მლრდ.
7,25 მლრდ.
Total operating expenses
9,10 მლრდ.
10,63 მლრდ.
10,02 მლრდ.
10,52 მლრდ.
Operating income
8,50 მლრდ.
8,66 მლრდ.
9,78 მლრდ.
12,46 მლრდ.
Other non operating income
-9,10 მლნ.
181,20 მლნ.
170,00 მლნ.
561,00 მლნ.
EBT including unusual items
7,23 მლრდ.
8,27 მლრდ.
8,85 მლრდ.
9,25 მლრდ.
EBT excluding unusual items
8,21 მლრდ.
8,89 მლრდ.
9,71 მლრდ.
12,73 მლრდ.
Income tax expense
1,65 მლრდ.
1,63 მლრდ.
1,45 მლრდ.
2,15 მლრდ.
Effective tax rate
22,81%
19,70%
16,43%
23,27%
Other operating expenses
-
-
-
-
Net income
5,58 მლრდ.
6,64 მლრდ.
7,40 მლრდ.
7,10 მლრდ.
Net profit margin
31,72%
34,41%
37,36%
30,88%
Earnings per share
7,02
7,54
8,55
8,38
Interest and investment income
65,00 მლნ.
672,40 მლნ.
-
-
Interest expense
-179,60 მლნ.
-153,30 მლნ.
-332,00 მლნ.
-345,00 მლნ.
Net interest expenses
-114,60 მლნ.
519,10 მლნ.
-332,00 მლნ.
-345,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
8,97 მლრდ.
9,25 მლრდ.
10,29 მლრდ.
12,99 მლრდ.
Gain or loss from assets sale
-
-180,00 მლნ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები